Madrigal Pharmaceuticals Target Price

Where could MDGL trade next? Consensus target price: $660.

Get informed when a big investor buys or sells

+ Follow

Share Price

$515.34

Average Target Price

$664.63

29% upside

8 analysts in the last 4 months

High: $962 | Low: $542

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-04	Wolfe Research	$605	17.4% upside
2026-07-31	Barclays	$962	86.7% upside
2026-07-29	Canaccord Genuity	$587	13.9% upside
2026-07-27	Wells Fargo	$685	32.9% upside
2026-06-11	Morgan Stanley	$542	5.2% upside
2026-05-13	Truist Financial	$709	37.6% upside
2026-05-07	Evercore ISI	$649	25.9% upside
2026-05-07	Canaccord Genuity	$578	12.2% upside
2026-01-27	Barclays	$964	87.1% upside
2026-01-14	Goldman SachsAndrea Tan	$571	10.8% upside
2026-01-06	Wolfe ResearchAndy Chen	$579	12.4% upside
2025-12-19	Piper SandlerYasmeen Rahimi	$900	74.6% upside
2025-12-19	UBS	$900	74.6% upside
2025-11-21	H.C. Wainwright	$620	20.3% upside
2025-11-20	OppenheimerJay Olson	$650	26.1% upside
2025-11-19	Truist Financial	$640	24.2% upside
2025-11-05	JMP Securities	$527	2.3% upside
2025-10-15	Piper Sandler	$540	4.8% upside
2025-10-14	Truist Financial	$580	12.5% upside
2025-10-10	OppenheimerJay Olson	$590	14.5% upside
2025-05-02	Canaccord GenuityEdward Nash	$420	18.5% downside
2024-05-29	Piper SandlerYasmeen Rahimi	$336	34.8% downside
2024-05-09	H.C. WainwrightEd Acre	$390	24.3% downside
2024-03-19	Evercore ISILiisa Bayko	$405	21.4% downside
2024-03-15	UBSEliana Merle	$410	20.4% downside
2024-03-15	JefferiesAkash Tewari	$400	22.4% downside
2024-03-15	H.C. WainwrightEd Acre	$425	17.5% downside
2024-03-15	JMP SecuritiesJonathan Wolleben	$397	23% downside
2024-03-15	B.Riley FinancialMayank Mamtani	$270	47.6% downside
2023-01-05	JMP Securities	$390	24.3% downside
2022-12-21	UBS	$337	34.6% downside
2022-12-20	H.C. Wainwright	$225	56.3% downside
2022-12-20	Oppenheimer	$250	51.5% downside
2022-12-20	Goldman Sachs	$375	27.2% downside
2022-12-20	JMP Securities	$312	39.5% downside
2022-12-20	Leerink Partners	$315	38.9% downside
2021-08-06	BMO CapitalMatthew Luchini	$111	78.5% downside
2021-05-20	Goldman SachsAndrea Tan	$195	62.2% downside
2021-05-06	Wells FargoDerek Archila	$130	74.8% downside

Madrigal Pharmaceuticals (MDGL) FAQ

Madrigal Pharmaceuticals's target price stands at $660. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $660 for MDGL implies 29.0% upside versus today's price ($515.34). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Madrigal Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places MDGL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Madrigal Pharmaceuticals's reading of $660 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.